Risk factors and mortality associated with calciphylaxis in end-stage renal disease

被引:252
|
作者
Mazhar, AR
Johnson, RJ
Gillen, D
Stivelman, JC
Ryan, MJ
Davis, CL
Stehman-Breen, CO
机构
[1] VA Puget Sound Hlth Care Syst, Div Nephrol, Seattle, WA 98108 USA
[2] Univ Washington, Div Nephrol, Seattle, WA 98195 USA
[3] Baylor Coll Med, Div Nephrol, Houston, TX USA
[4] Univ Washington, Grad Sch Publ & Int Affairs, Dept Biostat, NW Kidney Ctr, Seattle, WA 98195 USA
关键词
hyperphosphatemia; alkaline phosphatase and calciphylaxis; serum albumin and calciphylaxix; death and calciphylaxis; skin lesions and mortality;
D O I
10.1046/j.1523-1755.2001.00803.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. We conducted a case control study to determine risk factors and mortality associated with calciphylaxis in endstage renal disease. Methods. Cases of calciphylaxis diagnosed between December 1989 and January 2000 were identified. Three controls were identified for each hemodialysis patient, with calciphylaxis matched to the date of initiation of hemodialysis. Laboratory data and medication doses were recorded during the 12 months prior to the date of diagnosis and at the time of diagnosis of calciphylaxis. Conditional logistic regression was used to identify risk factors for calciphylaxis. Cox proportional hazards models were used to estimate the risk of death associated with calciphylaxis. Results. Nineteen cases and 54 controls were identified. Eighteen patients were hemodialysis patients, and one had a functioning renal allograft. Diagnosis was confirmed by skin biopsy in 16 cases. Women were at a sixfold higher risk of developing calciphylaxis (OR = 6.04, 95% CI 1.62 to 22.6, P = 0.007). There was a 21% lower risk of calciphylaxis associated with each 0.1 g/dL increase in the mean serum albumin during the year prior to diagnosis and at the time of diagnosis of calciphylaxis (OR = 0.79. 95% CI. 0.64 to 0.99. P = 0.037, and OR = 0.80. 95% CI. 0.67 to 0.96, P = 0.019, respectively). There was a 3.51-fold increase in the risk of calciphylaxis associated with each mg/dL increase in the mean serum phosphate during the year prior to diagnosis (95% CI. 0.99 to 12.5, P = 0.052). At the time of diagnosis of calciphylaxis. for each 10 IU/L increment in alkaline phosphatase, the risk of calciphylaxis increased by 19% (OR = 1.19. 95% CI. 1.00 to 1.40, P = 0.045). Body mass index, diabetes. blood pressure, aluminum, and higher dosage of erythropoietin and iron dextran were not independent predictors of calciphylaxis. Calciphylaxis independently increased the risk of death by eightfold (OR = 8.58. 95% CI. 3.26 to 22.6. P < 0.001). Conclusions. Female gender, hyperphosphatemia. high alkaline phosphatase, and low serum albumin are risk factors For calciphylaxis. Calciphylaxis is associated with a very high mortality.
引用
收藏
页码:324 / 332
页数:9
相关论文
共 50 条
  • [1] Calciphylaxis in End-Stage Renal Disease: A Rare Condition With High Mortality
    Bachu, Ramya
    Patel, Tanvi H.
    Hemmings, Stefan
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (07)
  • [2] Calciphylaxis in a patient with end-stage renal disease
    Kim, YJ
    Chung, BS
    Choi, KC
    JOURNAL OF DERMATOLOGY, 2001, 28 (05): : 272 - 275
  • [3] Calciphylaxis in pediatric end-stage renal disease
    Abubakr A. Imam
    Tej K. Mattoo
    Gaurav Kapur
    David A. Bloom
    Rudolph P. Valentini
    Pediatric Nephrology, 2005, 20 : 1776 - 1780
  • [4] Calciphylaxis in pediatric end-stage renal disease
    Imam, AA
    Mattoo, TK
    Kapur, G
    Bloom, DA
    Valentini, RP
    PEDIATRIC NEPHROLOGY, 2005, 20 (12) : 1776 - 1780
  • [5] RISK FACTORS FOR MORTALITY IN PATIENTS WITH SCHIZOPHRENIA AND END-STAGE RENAL DISEASE
    Jackson, A. J.
    Colombo, R.
    Baer, S.
    Young, L.
    Waller, J.
    Kheda, M.
    Nahman, S.
    Spearman, V.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2018, 66 (02) : 599 - 599
  • [6] Risk factors and mortality in patients with listeriosis and end-stage renal disease
    Tran, Sarah Y.
    Barry, Sauveur
    Waller, Jennifer L.
    Bollag, Wendy B.
    Young, Lufei
    Padala, Sandeep
    Baer, Stephanie L.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2023, 366 (04): : 263 - 269
  • [7] Calciphylaxis in end-stage renal disease patients Reply
    Hayashi, Matsuhiko
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (09) : 3663 - 3664
  • [8] Tumour Calcification and Calciphylaxis in End-Stage Renal Disease
    Di, Jia
    Jiang, Zhenxing
    Yang, Min
    CASE REPORTS IN MEDICINE, 2014, 2014
  • [9] SLEEP APNEA IN END-STAGE RENAL DISEASE PATIENTS: RISK FACTORS AND MORTALITY
    Prabu, P.
    Waller, J.
    Linder, D.
    Bollag, W.
    Mohammed, A. A.
    Nahman, S.
    Kheda, M.
    Baer, S. L.
    Padala, S.
    Taskar, V.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2020, 68 (02) : 666 - 666
  • [10] Sleep apnea in end-stage renal disease patients: risk factors and mortality
    Prabu, Pranav
    Acree, Lillian
    Waller, Jennifer L.
    Linder, Daniel F.
    Bollag, Wendy B.
    Mohammed, Azeem
    Padala, Sandeep
    Healy, William
    Kheda, Mufaddal
    Baer, Stephanie L.
    Dillard, Thomas
    Taskar, Varsha
    JOURNAL OF INVESTIGATIVE MEDICINE, 2023, 71 (05) : 465 - 470